Clinical Trial Update: A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer

View source ↗

Summary

A post-marketing safety study of abiraterone acetate (Zytiga) in Indian participants with metastatic castration-resistant prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Zytiga (abiraterone acetate)

Snippet

Sponsor: Johnson & Johnson Private Limited | Conditions: Prostate Cancer | Status: WITHDRAWN